Ombitasvir/paritaprevir/ritonavir + Dasabuvir Generics - Manufacturers & Suppliers
Viekira Pak® (US); Viekirax® + Exviera® (EU)
| Product/Composition:- | Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir |
|---|---|
| Strength:- | Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet) |
| Form:- | Tablet |
| Reference Brands:- | Viekira Pak® (US); Viekirax® + Exviera® (EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir, marketed as Viekira Pak® (US) and Viekirax® + Exviera® (EU), is a fixed-dose oral combination for Hepatitis C genotype 1. Approved by FDA and EMA, it offers an effective interferon-free treatment option, often used with ribavirin in B2B supply for global pharmaceutical markets.
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is a fixed-dose combination therapy used in the treatment of chronic Hepatitis C genotype 1. Marketed as Viekira Pak® in the US and Viekirax® + Exviera® in the EU, this regimen includes four direct-acting antivirals that target multiple stages of the HCV replication cycle. It offers a non-interferon-based treatment, often in combination with ribavirin. EMA and FDA approved, it’s a key option for B2B pharmaceutical partners sourcing branded and generic HCV therapies. Suitable for hospital, retail, and tender supply in regulated and semi-regulated markets. Available in tablet form with clearly defined daily dosing.